UniQure to file gene therapy for approval, reflecting major shifts at FDA
BioPharma Dive
The decision marks another regulatory U-turn following the exits of Marty Makary and Vinay Prasad, suggesting to some analysts that current FDA leadership may be more flexible in certain cases.
pharminent
June 17, 2026 (Last updated: June 19, 2026)
BioPharma Dive
The decision marks another regulatory U-turn following the exits of Marty Makary and Vinay Prasad, suggesting to some analysts that current FDA leadership may be more flexible in certain cases.
